Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Gogtay, Nithya ^a   Kannan, Sridharan ^a   Thatte, Urmila M ^a   Olliaro, Piero L ^b   Sinclair, David ^c  

^a KEM HOSPITAL   (India)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRONARIDINE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUOCOTEXIN; GUILAN; HEMOGLOBIN; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FANASIL, PYRIMETHAMINE DRUG COMBINATION; FLUORENE DERIVATIVE; QUINOLINE DERIVATIVE; SULFADOXINE;

ADULT; AGED; BLOOD SMEAR; CAMBODIA; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG HALF LIFE; ENDEMIC DISEASE; FEMALE; HUMAN; INDIA; INDONESIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARASITE CLEARANCE; PARASITEMIA; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RELAPSE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THAILAND; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; DRUG RESISTANCE; MALARIA, VIVAX; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; METHODOLOGY; RECURRENT DISEASE;

ANTIMALARIALS; ARTEMISININS; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FLUORENES; HUMANS; MALARIA, VIVAX; PARASITEMIA; PRIMAQUINE; PYRIMETHAMINE; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; SULFADOXINE; RECURRENCE;

EID: 84899468212     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008492.pub3     Document Type: Review

References (74)

1. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, et al.Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Journal of Infectious Diseases 2004;190(10):1773-82.
2. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, et al.A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clinical Infectious Diseases 2005;41(4):425-32.
3. Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, et al.Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority trial. Malaria Journal 2010;9:105.
4. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al.Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases 2007;44(8):1067-74.
5. Hutagalung R, Paiphun L, Ashley EA, McGready R, Brockman A, Thwai KL, et al.A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malaria Journal 2005;4:46.
6. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, et al.A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine 2008;359(24):2545-57.
7. Kolaczinski K, Durrani N, Rahim S, Rowland M. Sulfadoxine-pyrimethamine plus artesunate compared with chloroquine for the treatment of vivax malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a randomised non-inferiority trial in eastern Afghanistan. Transactions of the Royal Society of Tropical Medicine and Hygeine 2007;101(11):1081-7.
8. Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S, et al.Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean Journal of Parasitology 2007;45(2):111-4.
9. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, et al.Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: A randomized controlled trial. Clinical Infectious Diseases 2011;53(10):977-84.
10. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Phyo AP, Valecha N, et al.Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: A randomized, double-blind, non-inferiority trial. PLoS One 2011;6(1):e14501.
11. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, et al.Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007;369(9563):757-65.
12. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, et al.Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 2006;367(9528):2075-85.
13. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, et al.Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infectious Diseases 2010;10(10):673-81.
14. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, et al.Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrobial Agents and Chemotherapy 2013;57(3):1128-35.
15. Batty KT, Le AT, Ilett KF, Nguyen PT, Powell SM, Nguyen CH, et al.A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. American Journal of Tropical Medicine and Hygiene 1998;59(5):823-7.
16. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, et al.Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. Journal of Infectious Diseases 2012;206(11):1771-80.
17. Dao NV, Cuong BT, Ngoa ND, Thuy le TT, The ND, Duy DN, et al.Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007;101(6):534-9.
18. Davis WA, Clarke PM, Siba PM, Karunajeewa HA, Davy C, Mueller I, et al.Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea. Bulletin of the World Health Organization 2011;89(3):211-20.
19. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infectious Diseases 2010;10(6):405-16.
20. Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, Looareesuwan S. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health 2004;35(3):570-4.
21. Hombhanje FW, Linge D, Saweri A, Kuanch C, Jones R, Toraso S, et al.Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malaria Journal 2009;8:196.
22. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, et al.Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrobial Agents and Chemotherapy 2012;57(2):818-26.
23. Luxemburger C, Price RN, Nosten F, Ter Kuile FO, Chongsuphajaisiddhi T, White NJ. Mefloquine in infants and young children. Annals of Tropical Paediatrics 1996;16(4):281-6.
24. Naing C, Aung K, Win DK, Wah MJ. Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries. Transactions of the Royal Society of Tropical Medicine and Hygiene 2010;104(11):695-705.
25. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, Kenangalem E, et al.Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrobial Agents and Chemotherapy 2007;51(11):4090-7.
26. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, et al.Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrobial Agents and Chemotherapy 2000;44(6):1680-5.
27. Rueangweerayut R, Phyo AP, Uthaisin C, Poravuth Y, Binh TQ, Tinto H, et al.Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. New England Journal of Medicine 2012;366(14):1298-309.
28. Senn N, Rarau P, Manong D, Salib M, Siba P, Reeder JC, et al.Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea. Clinical Infectious Diseases 2013;56(10):1413-20.
29. Thimasarn K, Sirichaisinthop J, Chanyakhun P, Palananth C, Rooney W. A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in eastern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health 1997;28(3):465-71.
30. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrobial Agents and Chemotherapy 2002;46(12):3947-53.
31. Tjitra E, Hasugian AR, Siswantoro H, Prasetyorini B, Ekowatiningsih R, Yusnita EA, et al.Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malaria Journal 2012;11:153.
32. van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathman I, Royce C, et al.Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrobial Agents and Chemotherapy 1998;42(1):135-9.
33. Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A. Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia. Acta Tropica 2010;113(2):105-13.
34. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. American Journal of Tropical Medicine and Hygiene 2011;84(1):137-40.
35. Zwang J, Ashley EA, Karema C, D'Alessandro U, Smithuis F, Dorsey G, et al.Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 2009;4(7):e6358.
36. Janssens B, van Herp M, Goubert L, Chan S, Uong S, Nong S, et al.A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Tropical Medicine and International Health 2007;12(2):251-9.
37. Shin CS, Kwak YG, Lee KD, Borghini-Fuhrer I, Miller RM, Duparc S. Treatment of Korean vivax malaria patients with the fixed-dose combination of pyronaridine: Artesunate. Tropical Medicine and International Health. 2011; Vol. 16:149.
38. van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, et al.Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquine-proguanil. Clinical Infectious Diseases 2002;35(12):1498-504.
39. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends in Parasitology 2009;25(5):220-7.
40. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, et al.Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. American Journal of Tropical Medicine and Hygiene 1997;56(6):621-6.
41. Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Current Infectious Disease Reports 2007;9(1):39-46.
42. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clinical Microbiology Reviews 2009;22(3):508-34.
43. Barcus JM, Basri H, Picarima H, Manyakori C, Sekartuti, Elyazar I, et al.Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. American Journal of Tropical Medicine and Hygiene 2007;77(5):984-91.
44. Bloland PB. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria [WHO/HTM/RBM/2003.50]. Geneva: World Health Organization, 2003.
45. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. American Journal of Tropical Medicine and Hygiene 1996;55(3):243-9.
46. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al.Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine 2009;361(5):455-67.
47. Galappaththy GNL, Omari AAA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD004389.pub2]
48. Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al.Plasmodium vivax and mixed infections are associated with severe malaria in children: A prospective cohort study from Papua New Guinea. PLoS Medicine 2008;5(6):e127.
49. Gething PW, Elyazar IRF, Moyes CL, Smith DL, Battle KE, Guerra CA, et al.A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Neglected Tropical Diseases 2012;6(9):e1814.
50. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al.Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases 2007;44(8):1067-74.
51. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al.Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. Journal of Infectious Diseases 2007;195(7):927-33.
52. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, et al.A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine 2008;359(24):2545-57.
53. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, et al.Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. American Journal of Tropical Medicine and Hygiene 2009;80(2):194-8.
54. Mayxay M, Pukrittayakamee S, Newton PN, White NJ. Mixed-species malaria infections in humans. Trends in Parasitology 2004;20(5):233-40.
55. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax infection. American Journal of Tropical Medicine and Hygiene 2001;64(1-2 Suppl):97-106.
56. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene 2007;77(6 Suppl):181-92.
57. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, et al.Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996;347(9016):1654-8.
58. Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, et al.Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. American Journal of Tropical Medicine and Hygiene 1999;60(4):547-55.
59. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected but not benign. American Journal of Tropical Medicine and Hygiene 2007;77(Suppl 6):79-87.
60. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Current Opinion in Infectious Diseases 2009;22(5):430-5.
61. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al.Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007;101(4):351-9.
62. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open label randomised comparison. Lancet 2007;369(9563):757-65.
63. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
64. Sinclair D, Zani B, Donegan S, Oliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007483.pub2]
65. Sumawinata IW, Bernadeta, Leksana B, Sutamihardja A, Purnomo, Subianto B, et al.Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. American Journal of Tropical Medicine and Hygiene 2003;68(4):416-20.
66. Sutanto I, Suprijanto S, Nurhayati, Manoempil P, Baird JK. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. American Journal of Tropical Medicine and Hygiene 2009;81(2):338-42.
67. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, et al.Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. Journal of Infectious Diseases 2001;183(8):1254-9.
68. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Safety 2004;27(1):25-61.
69. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al.Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Medicine 2008;5(6):e128.
70. White NJ, Olliaro PL. Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitology Today 1996;12(10):399-401.
71. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al.Averting a malaria disaster. Lancet 1999;353(9168):1965-7.
72. White NJ. The assessment of antimalarial drug efficacy. Trends in Parasitology 2002;18(10):458-64.
73. World Health Organization. Guidelines for the treatment of malaria. 2nd Edition. Geneva: World Health Organization, 2010.
74. WHO. World Malaria Report. Geneva: World Health Organization, 2012.